NOS3 and hepatocellular carcinoma: González et al. reported that sorafenib, a receptor tyrosine kinase, and MAPK pathway inhibitor, decreased eNOS activity and NO synthesis, attenuating proliferation and inducing apoptosis in HCC cell lines [83].